I'm LongbridgeAI, I can summarize articles.Charles River Laboratories has entered a collaboration with Arovella Therapeutics to provide GMP next-generation sequencing services for cell bank characterization. Additionally, Charles River will conduct viral safety release testing for clinical batches of ALA-101, an off-the-shelf CAR-iNKT therapy targeting CD19+ lymphomas and leukemias. This partnership supports Arovella's IND filing.
- Charles River entered a collaboration with Arovella Therapeutics to provide GMP next-generation sequencing services for cell bank characterization. * FDA acceptance of NGS viral safety testing supported Arovella’s IND for two cell banks used in the ALA-101 manufacturing process. * Charles River will also run viral safety release testing for clinical batches of ALA-101, an off-the-shelf CAR-iNKT therapy targeting CD19+ lymphomas, leukemias. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260713900156) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)